Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, Lecia V., Waltman, Belinda A., Dias-Santagata, Dora, Digumarthy, Subba, Turke, Alexa B., Fidias, Panos, Bergethon, Kristin, Shaw, Alice T. +14 more·2011·Science Translational Medicine
DOI 10.1126/scitranslmed.3002003

Cited by (1,021)

Items 801–900 of 1,021

  1. The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
    Shang‐Gin Wu, Yih‐Leong Chang, Chong‐Jen Yu, Pan‐Chyr Yang, Jin‐Yuan Shih · 2016 · Scientific Reports
  2. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma
    Rita Tohmé, Sudeh Izadmehr, Sai Gandhe, Giancarlo Tabaro, Sanjay Vallabhaneni, Ava Thomas, Neal Vasireddi, Neil S. Dhawan, Avi Ma’ayan, Neelesh Sharma et al. · 2019 · JCI Insight
  3. A BRAF new world
    Daniele Frisone, Alex Friedlaender, Umberto Malapelle, Giuseppe Luigi Banna, Alfredo Addeo · 2020 · Critical Reviews in Oncology/Hematology
  4. Review of the current targeted therapies for non-small-cell lung cancer
    Kim-Son Hoa Nguyen · 2014 · World Journal of Clinical Oncology
  5. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
    Meghan J. Campo, H. Al-Halabi, Melin Janardan Khandekar, Alice Tsang Shaw, Lecia Van Dam Sequist, Henning Willers · 2016 · The Oncologist
  6. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
    Yen‐Ting Lin, Jin‐Shing Chen, Wei‐Yu Liao, Chao‐Chi Ho, Chia‐Lin Hsu, Ching‐Yao Yang, Kuan‐Yu Chen, Jih‐Hsiang Lee, Zhong‐Zhe Lin, Jin‐Yuan Shih et al. · 2018 · International Journal of Cancer
  7. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib
    G. Veerman, Mei H. Lam, Ron H.J. Mathijssen, Stijn L.W. Koolen, Peter de Bruijn · 2019 · Journal of Chromatography B
  8. Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer, and Computational Studies
    Mohammad Mahboob Alam, Syed Nazreen, Abdulraheem S. A. Almalki, Ahmed A. Elhenawy, Nawaf I. Alsenani, Serag Eldin I. Elbehairi, Azizah M. Malebari, Mohammad Yahya Alfaifi, Meshari A. Alsharif, Sulaiman Alfaifi · 2021 · Pharmaceuticals
  9. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
    Alfredo Tartarone, Chiara Lazzari, Rosa Lerose, Vincenza Conteduca, Giuseppina Improta, Angela Zupa, Alessandra Bulotta, Michele Aieta, Vanesa Gregorc · 2013 · Lung Cancer
  10. Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition
    Chung Choe, Yong-Sung Shin, So‐Jung Choi, Jinseon Lee, So Young Kim, Yong Beom Cho, Jhingook Kim, Changhoon Kim · 2015 · OncoTargets and Therapy
  11. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
    Soomin Ahn, Soo Hyun Hwang, Joungho Han, Yoon‐La Choi, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn, Woong‐Yang Park · 2016 · Journal of Pathology and Translational Medicine
  12. IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
    Romaine Ingrid Fernando, Duane H. Hamilton, Charli L. Dominguez, Justin M. David, Kristen K. McCampbell, Claudia Palena · 2016 · Oncotarget
  13. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Reyes Bernabé, Nicholas Hickson, Andrew J. Wallace, Fiona Helen Blackhall · 2017 · European Journal of Cancer
  14. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs
    Choong‐kun Lee, Sora Kim, Jeong Eun Lee, Jeong Eun Lee, Sung-moo Kim, In Seok Yang, Hye Ryun Kim, Jeong Ho Lee, Sangwoo Kim, Byoung Chul Cho · 2017 · Lung Cancer
  15. High cholesterol in lipid rafts reduces the sensitivity to EGFR‐TKI therapy in non‐small cell lung cancer
    Qiufang Chen, Zhenzhen Pan, Min Zhao, Qin Wang, Chen Qiao, Liyun Miao, Xuansheng Ding · 2017 · Journal of Cellular Physiology
  16. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer
    Conor Ernst Steuer, Fadlo Raja Khuri, Suresh S. Ramalingam · 2014 · Cancer
  17. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
    Tristan Alexandra Barnes, Grainne Mary O'Kane, Mark David Vincent, Natasha B. Leighl · 2017 · Frontiers in Oncology
  18. Resistance to molecularly targeted therapy in non-small-cell lung cancer
    Tetsuhiko Asao, Fumiyuki Takahashi, Kazuhisa Takahashi · 2018 · Respiratory Investigation
  19. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
    Hidetoshi Hayashi, Ernest Nadal, Jhanelle E. Gray, Andrea Ardizzoni, N. Caria, Tarun Puri, Christian Grohé · 2021 · Clinical Lung Cancer
  20. Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
    Johannes M. Heuckmann, Daniel Rauh, Roman Kurt Thomas · 2012 · Journal of Clinical Oncology
  21. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC
    Cecile Bosc, G. Ferretti, Jacques L. Cadranel, Clarisse Audigier-Valette, Benjamin Besse, Fabrice Barlési, Chantal Decroisette, Sylvie Lantuéjoul, François Arbib, Denis Moro‐Sibilot · 2014 · Targeted Oncology
  22. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation
    Clement Chung, Matthew Christianson · 2013 · Journal of Oncology Pharmacy Practice
  23. Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non–Small Cell Lung Cancer
    Timothy Francis Burns, Irina Dobromilskaya, Sara C. Murphy, Rajendra P. Gajula, Saravanan Thiyagarajan, Sarah N.H. Chatley, Khaled Aziz, Yoon‐Jae Cho, Phuoc Tho Tran, Charles M. Rudin · 2013 · Molecular Cancer Research
  24. Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
    Geoffrey R. Oxnard, Yelena Yuriy Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha Lindsay Kass, Gregory J. Riely, William J. Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli et al. · 2011 · Clinical Cancer Research
  25. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
    Stephen W. Jarantow, Barbara S. Bushey, José R. Pardinas, Ken Boakye, Eilyn R. Lacy, Renouard Sanders, Manuel A. Sepúlveda, Sheri L. Moores, Mark L. Chiu · 2015 · Journal of Biological Chemistry
  26. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
    Yaqiong Tian, Zengli Zhang, Liyun Miao, Zhimin Yang, Jie Yang, Yinhua Wang, Danwen Qian, Hourong Cai, Yongsheng Wang · 2016 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  27. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
    Wei Lou, Yan Chen, Keying Zhu, Huizi Deng, Tianhao Wu, Jun Wang · 2017 · Biological and Pharmaceutical Bulletin
  28. Is tissue still the issue in detecting molecular alterations in lung cancer?
    Chong Kin Liam, Sugamya Mallawathantri, Kwun Meng Fong · 2020 · Respirology
  29. Advances in Small-Cell Lung Cancer (SCLC) Translational Research
    Benjamin Jacob Drapkin, Charles M. Rudin · 2020 · Cold Spring Harbor Perspectives in Medicine
  30. Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
    Lin Li, Hui Wang, Chao Li, Zheng Wang, Ping Zhang, Yan Xu · 2017 · Oncotarget
  31. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
    Vincenzo Di Noia, Alessandro D’Aveni, Ettore D’Argento, Sabrina Rossi, Paolo Ghirardelli, Luigi Bortolotti, V. Vavassori, Emilio Bria, Giovanni Luca Ceresoli · 2021 · ESMO Open
  32. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)
    Ziad Abuhelwa, Abdurahman Alloghbi, Misako Nagasaka · 2022 · Cancer Treatment Reviews
  33. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase‐dependent mechanism
    Victor Jeannot, Benoît Busser, Elisabeth M. Brambilla, Marie Wislez, Blaise Robin, Jacques L. Cadranel, Jean‐Luc Coll, Amandine Hurbin · 2013 · International Journal of Cancer
  34. Development of c-MET pathway inhibitors
    Xiangdong Liu, Robert Charles Newton, Peggy Scherle · 2011 · Expert Opinion on Investigational Drugs
  35. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma
    Guoping Cai, Rebecca A. Wong, David C. Chhieng, Gillian H. Levy, Scott N. Gettinger, Roy S. Herbst, Jonathan T. Puchalski, Robert Homer, Pei Hui · 2013 · Cancer Cytopathology
  36. HSP90 inhibitors in lung cancer: promise still unfulfilled.
    Suman Chatterjee, Saveri Bhattacharya, Mark A. Socinski, Timothy Francis Burns · 2016 · PubMed
  37. China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)
    Yuankai Shi, Yan Ping Sun, Jinming Yu, Cuimin Ding, Ziping Wang, Changli Wang, Dong Wang, Cunde Wang, Zheng Wang, Mengzhao Wang et al. · 2016 · Asia-Pacific Journal of Clinical Oncology
  38. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non–small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
    Bo Qiu, Ying Liang, Qi-Wen Li, Gui-hong Liu, Fang Wang, ZhaoLin Chen, Mengzhong Liu, Ming Dan Zhao, Hui Liu · 2017 · Clinical Lung Cancer
  39. Molecular Profiling of Malignant Pleural Effusion in Metastatic Non–Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors
    Jamal H. Carter, James Adam Miller, David J Feller-Kopman, David S. Ettinger, David Sidransky, Zahra Maleki · 2017 · Annals of the American Thoracic Society
  40. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
    Jia Zhong, Lei Li, Zhijie Wang, Hua Bai, Fei Gai, Jianchun Duan, Jun Zhao, Minglei Zhuo, Yuyan Wang, Shuhang Wang et al. · 2017 · Journal of Thoracic Oncology
  41. Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review
    Hiroki Izumi, Akira Yamasaki, Yasuto Ueda, Takashi Sumikawa, Hiroyuki Maeta, Shu Nakamoto, Eiji Shimizu · 2017 · Clinical Lung Cancer
  42. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Kun‐Chieh Chen, Chia-Hung Hsu, Kang‐Yi Su, Jeremy J.W. Chen, Huei‐Wen Chen, Sung‐Liang Yu, Tsung‐Ying Yang et al. · 2018 · Cancer Research and Treatment
  43. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics
    Peiye Shen, Ying Jing, Ruiyun Zhang, Mei‐Chun Cai, Pengfei Ma, Haige Chen, Guanglei Zhuang · 2018 · Oncogene
  44. Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
    Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick H. Dinkelborg, Heike N. Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia Van Dam Sequist, Kerstin Borgmann et al. · 2019 · Cell Reports
  45. Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer
    Franziska Böttger, Ekaterina A. Semenova, Ji‐Ying Song, Giustina Ferone, Jan van der Vliet, Miranda Cozijnsen, Rajith Bhaskaran, Lorenzo Bombardelli, Sander R. Piersma, Thang V. Pham et al. · 2019 · Cell Reports
  46. Imaging of Precision Therapy for Lung Cancer: Current State of the Art
    Hyesun Park, Lynette Marie Sholl, Hiroto Hatabu, Mark Magdi Awad, Mizuki Nishino · 2019 · Radiology
  47. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
    Yi-Chen Zhang, Qing Hua Zhou, Yi-Long Lung Cancer Wu · 2017 · Journal of Hematology & Oncology
  48. Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer
    Mohamed Aly Haider, Amr Elsherbeny, Valeria Pittalà, Antonino Nicolò Fallica, Maha Ali Alghamdi, Zahid Hussain, Ghalia Khoder, Khaled F. Greish · 2022 · International Journal of Molecular Sciences
  49. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
    Ryo Ko, Hirotsugu Kenmotsu, Masakuni Serizawa, Yasuhiro Koh, Kazushige Wakuda, Akira Ono, Tetsuhiko Taira, Tateaki Naito, Haruyasu Murakami, Mitsuhiro Isaka et al. · 2016 · BMC Cancer
  50. The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations
    Angela Espósito, Carmen Criscitiello, Dario Trapani, Giuseppe Curigliano · 2017 · Current Oncology Reports
  51. SBRT for oligoprogressive oncogene addicted NSCLC
    Lucas Basler, Stephanie G. C. Kroeze, Matthias Gückenberger · 2017 · Lung Cancer
  52. Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
    Daniel J. de Klerk, Richard J. Honeywell, Gerrit Jansen, Godefridus J. Peters · 2018 · Cancers
  53. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
    Jeffrey H. Becker, Yandi Gao, Margaret Soucheray, Inés Pulido, Eiki Kikuchi, María L. Rodríguez, Rutu Gandhi, Aránzazu Lafuente-Sanchis, Miguel Aupí, Javier Alcácer Fernández-Coronado et al. · 2019 · Cancer Research
  54. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
    Paul Workman, Bissan Al‐Lazikani, Paul Andrew Clarke · 2013 · Current Opinion in Pharmacology
  55. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
    Peter Stephen Savas, Brett G.M. Hughes, Benjamin Solomon · 2013 · Europe PMC (PubMed Central)
  56. Investigating Tumor Heterogeneity in Mouse Models
    Tuomas Tammela, Julien Sage · 2019 · Annual Review of Cancer Biology
  57. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
    Paolo Maione, Paola Claudia Sacco, Assunta Sgambato, Francesca Casaluce, Antônio Rossi, Cesare Gridelli · 2015 · Therapeutic Advances in Medical Oncology
  58. Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
    Antonio Marchetti, Maela Del Grammastro, Giampaolo Filice, Lara Felicioni, Giulio Rossi, Paolo Graziano, Giuliana Sartori, Alvaro Leone, Sara Malatesta, Michele Iacono et al. · 2012 · PLoS ONE
  59. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
    Jhanelle E. Gray, Eric B. Haura, Alberto Chiappori, Tawee Tanvetyanon, Charles C. Williams, Mary C. Pinder-Schenck, Julie Ann Kish, Jenny M. Kreahling, Richard M. Lush, Anthony M. Neuger et al. · 2014 · Clinical Cancer Research
  60. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
    Hiroki Sato, Kazuhiko Shien, Shuta Tomida, Kazuhiro Okayasu, Ken Suzawa, Shinsuke Hashida, Hidejiro Torigoe, Mototsugu Watanabe, Hiromasa Yamamoto, Junichi Soh et al. · 2017 · Scientific Reports
  61. Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
    Chia‐Yu Chu, Jennifer Nam Choi, Beth Eaby‐Sandy, Corey Jay Langer, Mario E. Lacouture · 2018 · The Oncologist
  62. Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
    Ziyi Xu, Junling Li · 2019 · OncoTargets and Therapy
  63. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
    Zeng, Hao, Castillo-Cabrera, Johnny, Manser, Mika, Lu, Bo, Yang, Zinger, Strande, Vaik, Begue, Damien, Zamponi, Raffaella, Qiu, Shumei, Sigoillot, Frederic et al. · 2019 · eLife
  64. Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
    Spaans, Johanna N., Goss, Glenwood D. · 2014 · Frontiers in Oncology
  65. The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities
    Meghna Das Thakur, Darrin D. Stuart · 2013 · Cancer Research
  66. The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
    Carmelo Laface, Felicia Maria Maselli, Anna Natalizia Santoro, Maria Laura Iaia, Francesca Ambrogio, Marigia Laterza, Chiara Guarini, Pierluigi De Santis, Martina Perrone, Palma Fedele · 2023 · Pharmaceutics
  67. Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE
    Jayeon Song, Mi Hyeon Cho, Hayoung Cho, Younseong Song, Sung-Woon Lee, Ho Chul Nam, Tae-Ho Yoon, Jong Cheol Shin, Jae‐Sang Hong, Yejin Kim et al. · 2024 · Nature Biotechnology
  68. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression
    Kevin M. Kalinsky, Adriana Heguy, Umesh Kumar Bhanot, Sujata N Patil, Mary Ellen Moynahan · 2011 · Breast Cancer Research and Treatment
  69. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
    Akihiro Kogita, Yosuke Togashi, Hidetoshi Hayashi, Shunsuke Sogabe, Masato Terashima, Marco Antonio De Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Yoshifumi Takeyama et al. · 2014 · International Journal of Oncology
  70. Clinical perspective of afatinib in non-small cell lung cancer
    Xiaofeng Chen, Quan Zhu, Lingjun Zhu, Dong Pei, Yiqian Liu, Yongmei Yin, Martin Schüler, Yongqian Shu · 2013 · Lung Cancer
  71. Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis
    Xiao-Hong Kang, Zhen-Ye Xu, Ya-Bin Gong, Li‐Fang Wang, ZhongQi Wang, Ling Xu, Fei Cao, Ming-juan Liao · 2013 · Evidence-based Complementary and Alternative Medicine
  72. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
    Hannah A. Scarborough, Barbara A. Helfrich, Matias Casás‐Selves, Alwin G. Schuller, Shaun E. Grosskurth, Jihye Kim, Aik Choon Tan, Daniel C. F. Chan, Zhiyong Zhang, Vadym Zaberezhnyy et al. · 2016 · Clinical Cancer Research
  73. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
    Tony S.K. Mok, Sarayut Lucien Geater, Wu‐Chou Su, Eng-Huat Tan, James Chih‐Hsin Yang, Gee‐Chen Chang, May Han, Philip B. Komarnitsky, Francis C. Payumo, Jennifer E. Garrus et al. · 2016 · Journal of Thoracic Oncology
  74. A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
    Helena Alexandra Yu, Leslie Perez, Qing Chang, Sizhi Paul Gao, Mark G. Kris, Gregory J. Riely, Jacqueline Bromberg · 2016 · Journal of Thoracic Oncology
  75. Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
    Yoon Soo Chang, Chang‐Min Choi, Jae Cheol Lee · 2016 · Tuberculosis & respiratory diseases
  76. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
    Ahmad Zulkifli, Fiona H. Tan, Tracy L. Putoczki, Stanley S. Stylli, Rodney Brian Luwor · 2017 · Molecular and Cellular Endocrinology
  77. Liquid biopsy genotyping in lung cancer: ready for clinical utility?
    Wei-Lun Huang, Yi-Lin Chen, Szu‐Chun Yang, Chung‐Liang Ho, Fang Wei, David T. Wong, Wu‐Chou Su, Chien‐Chung Lin · 2017 · Oncotarget
  78. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer
    Shigeki Nanjo, Sachiko Arai, Wei Wang, Shinji Takeuchi, Tadaaki Yamada, Akito Hata, Nobuyuki Katakami, Yasunori Okada, Seiji Yano · 2017 · Molecular Cancer Therapeutics
  79. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer
    Kaixian Zhang, Qianqian Yuan · 2016 · Journal of Cancer Research and Therapeutics
  80. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib
    Suchit H. Patel, Andreas Rimner, Amanda Foster, Zhigang Zhang, Kaitlin M. Woo, Helena Alexandra Yu, Gregory J. Riely, Abraham Jing-Ching Wu · 2017 · Lung Cancer
  81. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
    Saoirse Olivia Dolly, Dearbhaile Catherine Collins, Raghav Sundar, Sanjay Popat, Timothy A. Yap · 2017 · Drugs
  82. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance
    Yuxiang Ma, Xin Xiao Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai et al. · 2018 · Journal of Thoracic Oncology
  83. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis
    Xialing Huang, Liling Long, Wei Jieqin, Yajuan Li, Yuwei Xia, Panli Zuo, Xiangfei Chai · 2019 · Journal of Cancer Research and Clinical Oncology
  84. Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET
    Arpita S. Pal, Alejandra Agredo, Nadia A. Lanman, Jihye Son, Ikjot Singh Sohal, Manvir Bains, Chennan Li, Jenna Clingerman, Kayla Gates, Andrea L. Kasinski · 2022 · Cancer Research
  85. Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma
    Shiyu Jiang, Jing Zhao, Mengzhao Wang, Zhen Huo, Jing Zhang, Wei Zhong, Yan Xu · 2016 · Medicine
  86. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
    Laura Pacini, Andrew D. Jenks, Nadia Carvalho Lima, Paul H. Huang · 2021 · Cells
  87. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    Sangyong Jung, Dong Ha Kim, Yun Jung Choi, Seon Ye Kim, Hyojeong Park, Hyeonjeong Lee, Chang‐Min Choi, Young Hoon Sung, Jae Cheol Lee, Jin Kyung Rho · 2021 · Scientific Reports
  88. The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target
    Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio · 2022 · Journal of Oncology
  89. The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
    Xinming Li, Mingdong Li, Meiying Huang, Qianyi Lin, Qiuping Fang, Jianjiang Liu, Xiaohui Chen, Lin Liu, Xuliang Zhan, Huisi Shan et al. · 2022 · Biomedicine & Pharmacotherapy
  90. A stochastic model for immunotherapy of cancer
    Martina Baar, Loren Coquille, Hannah Mayer, Michael Hölzel, Meri Rogava, Thomas Tüting, Anton Bovier · 2016 · Scientific Reports
  91. MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases
    Jennifer M. Boland, Jin Sung Jang, Jun Li, Adam M. Lee, Jason A. Wampfler, Michele R. Erickson‐Johnson, Iberê Cauduro Soares, Ping Yang, Jin Jen, André M. Oliveira et al. · 2013 · Journal of Thoracic Oncology
  92. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer
    Agnes Stachnik, Tony Yuen, Jameel Z. Iqbal, Miriam Sgobba, Yogesh K. Gupta, Ping Lü, Graziana Colaianni, Yaoting Ji, Ling-Ling Zhu, Se‐Min Kim et al. · 2014 · Proceedings of the National Academy of Sciences
  93. Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Takuya Araki, Hideaki Yashima, Kimihiro Shimizu, Tohru Aomori, Tadahiro Hashita, Kyoichi Kaira, Tomonori Nakamura, Koujirou Yamamoto · 2012 · Clinical Medicine Insights Oncology
  94. Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
    Kenichi Suda, Kenji Tomizawa, Hirotaka Osada, Yoshihiko Maehara, Yasushi Yatabe, Yoshitaka Sekido, Tetsuya Mitsudomi · 2011 · Lung Cancer
  95. Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Aarif Ahsan · 2015 · Advances in experimental medicine and biology
  96. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
    Pasi Antero Janne, Alice Tsang Shaw, D. Ross Camidge, Giuseppe Giaccone, S. Martin Shreeve, Yiyun Tang, Zelanna Goldberg, Jean‐François Martini, Huiping Xu, Leonard Philip James et al. · 2016 · Journal of Thoracic Oncology
  97. EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review
    Yuri Sheikine, Deepa Rangachari, Danielle C. McDonald, Mark S. Huberman, Erik S. Folch, Paul A. VanderLaan, Daniel Botelho Costa · 2016 · Clinical Lung Cancer
  98. Molecular diagnostics of lung cancer in the clinic
    Lynette Marie Sholl · 2017 · Translational Lung Cancer Research
  99. Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
    Takashi Seto, Naoyuki Nogami, Nobuyuki Yamamoto, Shinji Atagi, Naoki Tashiro, Yoko Yoshimura, Yutaka Yabuki, Hideo Saka · 2018 · Oncology and Therapy
  100. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance
    Ankush Chandra, Arman Jahangiri, William C. Chen, Alan T. Nguyen, Garima Yagnik, Matheus Prado Pereira, Saket Jain, Joseph H. Garcia, Sumedh Subodh Shah, Harsh Wadhwa et al. · 2020 · Cancer Research